News | September 02, 2022
NATCO Pharma to sell stake in Nativita and assets of Pharma division
NATCO to sell 15% of shareholding in Nativita for euro 3,45,000 to Pharmasyntez-Nord
NATCO to sell 15% of shareholding in Nativita for euro 3,45,000 to Pharmasyntez-Nord
The capital expansion program commenced in June 2022 and is expected to complete in 2024
This dense phase often resembles liquid droplets exhibiting higher protein density and weaker molecular motion than the surrounding medium.
This launch builds upon Hikma’s leading position as one of the largest US providers of nasally administered medicines used for treating seasonal allergies and advances its objective of growing its specialty business in the US
The existing hospital premises has the scope to further scale up the bed capacity as and when required in the future with minimal Capex.
To mark the occasion, Integrated Pharmaceutical Database Management System 2.0 (IPDMS 2.0), an integrated responsive cloud-based application developed by NPPA with technical support from C-DAC will be launched
This industry-academia collaboration will provide students with an opportunity to participate in research activities with multiple international universities and scientists
Sandoz is planned to be incorporated in Switzerland and to be listed on the SIX Swiss Exchange, with an American Depositary Receipt (ADR) program in the US
Pending authorization, Moderna ready to ship bivalent booster mRNA-1273.222 in September
Glenmark continues to cooperate with the US FDA and is committed to undertake all necessary steps required to address their observations at the earliest.
Subscribe To Our Newsletter & Stay Updated
